‘Phase 1, 2, 3 and 4 trials’, Cancer Research UK, 6 September 2012, http://cancerhelp.cancerresearchuk.org/trials/types-of-trials/phase-1-2-3-and-4-trials

DiMasi, Joseph A. et al., ‘The price of innovation: new estimates of drug development costs’, Journal of Health Economics, Vol.22, 2003, pp.151-185, http://moglen.law.columbia.edu/twiki/pub/LawNetSoc/BahradSokhansanjFirstPaper/22JHealthEcon151_drug_development_costs_2003.pdf

Harris, Gwyn, ‘Pharmaceutical representatives do influence physician behaviour’, Family Practice, Vol.26 2009, pp.169-70, http://fampra.oxfordjournals.org/content/26/3/169.full

‘Special Access Programme – Drugs’, Health Canada, 15 August 2005, http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/sapfs_pasfd_2002-eng.php

Jenkins, John, ‘Considerations for Clinical Trial Designs’, U.S. Food and Drug Administration, https://rarediseases.info.nih.gov/files/Jenkins.pdf

‘Clinical trials and medical research – Phases of trials’, NHS Choices, 5 September 2011, http://www.nhs.uk/Conditions/Clinical-trials/Pages/Phasesoftrials.aspx

‘Compassionate Use of Unapproved Investigational Product’, Pfizer, http://www.pfizer.com/research/research_clinical_trials/compassionate_use_policy.jsp

Roy, Avik S. A., ‘Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials’, Project FDA Report, No. 5, April 2012, http://www.manhattan-institute.org/html/fda_05.htm

Schüklenk, Udo, and Lowry, Christopher, ‘Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments’, British Medical Bulletin, Vol.89, 2009, pp.7-22, http://bmb.oxfordjournals.org/content/89/1/7.full.pdf?keytype=ref&amp;ijkey=Ip64J5FUXThKvP0

‘Volunteer for research at UNClinicalStudies.org’, University of Michigan Comprehensive Cancer Center, http://www.cancer.med.umich.edu/living/clinical-trials.html

Wilson, Fred, "John Stuart Mill", in Edward N. Zalta (ed.), The Stanford Encyclopedia of Philosophy (Spring 2012 Edition), http://plato.stanford.edu/archives/spr2012/entries/mill/
